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Repositioning of Omarigliptin as
a once-weekly intranasal Antiparkinsonian Agent
Bassam M. Ayoub 1,2, Shereen Mowaka1,2,3, Marwa M. Safar2,4,5, Nermeen Ashoush2,6,
Mona G. Arafa2,7,8, Haidy E. Michel9, Mariam M. Tadros10, Mohamed M. Elmazar2,4 &
Shaker A. Mousa11
Drug repositioning is a revolution breakthrough of drug discovery that presents outstanding
privilege with already safer agents by scanning the existing candidates as therapeutic switching or
repurposing for marketed drugs. Sitagliptin, vildagliptin, saxagliptin & linagliptin showed antioxidant
and neurorestorative effects in previous studies linked to DPP-4 inhibition. Literature showed
that gliptins did not cross the blood brain barrier (BBB) while omarigliptin was the first gliptin that
crossed it successfully in the present work. LC-MS/MS determination of once-weekly anti-diabetic
DPP-4 inhibitors; omarigliptin & trelagliptin in plasma and brain tissue was employed after 2 h of oral
administration to rats. The brain/plasma concentration ratio was used to deduce the penetration power
through the BBB. Results showed that only omarigliptin crossed the BBB due to its low molecular
weight & lipophilic properties suggesting its repositioning as antiparkinsonian agent. The results of
BBB crossing will be of interest for researchers interested in Parkinson’s disease. A novel intranasal
formulation was developed using sodium lauryl sulphate surfactant to solubilize the lipophilic
omarigliptin with penetration enhancing & antimicrobial properties. Intranasal administration showed
enhanced brain/plasma ratio by 3.3 folds compared to the oral group accompanied with 2.6 folds
increase in brain glucagon-like peptide-1 concentration compared to the control group.
Parkinson’s disease (PD) is a neurodegenerative disease1. Glucagon-like peptide-1 (GLP-1) was reported as a
potential candidate in modifying neurodegenerative diseases as a promising antiparkinsonian effect of dipeptidyl
peptidase (DPP)-4 inhibitors (Gliptins) by exerting a neuroprotective effect in PD animal models2,3. Sitagliptin4–6,
vildagliptin7, saxagliptin8 & linagliptin9 showed anti-oxidant, anti-apoptotic and neuro-restorative mechanisms
in previous studies linked to DPP-4 inhibition10. Moreover, a recent study suggested repositioning of teneligliptin
to brain disorders11. Interestingly, omarigliptin (OG) & trelagliptin (TG) in this study were considered for the first
time to test their ability to cross the blood brain barrier (BBB) suggesting OG repositioning to brain disorders
based on its BBB crossing, its polypharmacology and potential increasing of GLP-1 concentration in the brain.
Drug repositioning is a hot research topic as an alternative to underperforming hypothesis-driven molecular target based drug discovery efforts12–15. De novo drug discovery is a traditional approach, which is costly and
time-consuming process. Thus, drug repositioning was an alternative approach as therapeutic switching or drug
repurposing for already marketed drug with less time consuming and less costly16. It has proved to be a preferred
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Figure 1. Chemical structures of omarigliptin (a) trelagliptin (b) and the internal standard, alogliptin (c).
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Table 1. Results obtained for the described LC-MS/MS method for determination of OG and TG in rats’
plasma & brain tissue. *Where LLOQ is the lower limit of quantification, LQC is the low quality control sample,
HQC is the high quality control sample, RE is the accuracy relative error, % RSD is the percent relative standard
deviation, ME is the matrix effect & IS (the internal standard).

strategy for accelerated drug discovery as a relatively inexpensive pathway that carries minimal risk due to availability
of previous pharmacological, safety and toxicology data17 with many successful suggested studies in the literature18–33.
OG (Fig. 1a) and TG (Fig. 1b) are new once weekly anti-diabetic drugs. Despite the fact that the initial therapy
of diabetes usually be with metformin, thereafter treatment should consider different second line options. These
include DPP-4 inhibitors, of which OG and TG are once weekly versions34,35. In contrast to the once-daily DPP-4
inhibitors, once-weekly administration can improve patients’ adherence36–43.
In the present work, sensitive and specific LC-MS/MS methods were developed and validated for estimation
of OG & TG in rats’ plasma and brain tissue to show their interaction with the BBB to check for the possibility of
their repositioning as antiparkinsonian agents. As per FDA guidelines44, a detailed validation of the LC-MS/MS
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Figure 2. Daughter ions mass spectra in positive ESI ion detection mode with the proposed fragments showing
m/z at 153.0, 134.1 & 116.1 for omarigliptin, trelagliptin & alogliptin, respectively.

methods was carried out. The proposed repositioning study of OG, after the proof of crossing BBB, will be of
interest for pharmaceutical industry & researchers working in the area of PD treatment with the major advantages
of repositioning that include safety, saving time & money. Preliminary investigations confirmed that alogliptin is a
suitable internal standard (IS) with similar physical and chemical properties while performing the simple sample
extraction procedures45–47 as shown in its structure presented in Fig. 1c.
Determination of drugs in animal brain tissue is common in the literature48–58 to check their crossing of BBB.
Various extraction techniques were employed for extraction of drugs either from brain homogenate alone50,51 or
from both animal plasma & brain extract50–56 including direct precipitation48–51; liquid-liquid extraction52–56, solid
phase extraction57 & QuEChERS based approach58. Moreover, direct precipitation was also used for simultaneous
extraction of eight neurotransmitters from brain tissue59. Results showed that OG crossed the blood brain barrier
(BBB) suggesting repositioning as antiparkinsonian agent. Moreover, a novel intranasal formulation was developed using sodium lauryl sulphate surfactant to solubilize the lipophilic omarigliptin with penetration enhancing
& antimicrobial properties. Intranasal administration to rats showed enhanced brain/plasma ratio by 3.3 folds
than the oral group accompanied with 2.6 folds increase in brain glucagon-like peptide-1 (GLP-1) concentration than the control group. Furthermore, the developed method used with rat plasma was extended to human
plasma and applied for bioassay of samples from twelve human volunteers. Because of change in the species, it
necessitated a partial validation study as the results of human QC samples showed (10–13%) lower recoveries
than rat samples, which might be attributed to higher binding affinity of the drugs to human plasma proteins due
to species difference60.

Methods

Chemicals and reagents. Human plasma, OG & TG (99.0%), MARIZEV (25 mg) & ZAFATEK (100 mg)
tablets were kindly donated by the Center for Drug Research and Development (CDRD, BUE) from a previous
project fund. HPLC grade acetonitrile, HPLC water & formic acid were purchased from Sigma Aldrich (USA).
Sandwich ELISA kit (CUSABIO, CSB-E08117r) was used for GLP-1 determination in rats’ brain tissue samples. Potassium dihydrogen phosphate was purchased from VWR Chemicals (Pool, England). The following surfactants were used as 2.5% (w/v) aqueous solutions: Sodium Lauryl Sulphate (SLS) and Tween-80 from (El-Nasr
Pharmaceutical Chemicals Co., Cairo, Egypt).
LC-MS/MS conditions.

The same LC-MS/MS instrument & chromatographic conditions described by the
same authors (Bassam Ayoub & Shereen Mowaka) for TG & IS (alogliptin) assay61 were adopted and extended
to include OG in the current work. Furthermore, collision energy of 30 eV and cone voltage of 30 V was found to
be suitable for MRM of OG using the same other reported mass detection parameters61. “WATERS UPLC system
(USA), TQ detector supplemented with electrospray ionization source (USA) and Agilent SB-C18 column with
dimensions (1.8 µm) 50 × 2.1 mm was used. Mass Lynx software version 4.1 was used. A mixture of acetonitrile formic acid 0.1% (80:20, v/v) was used as the mobile phase, filtered via a filter membrane with 0.2 µm pore size and
it was degassed for 25 min. Injection volume of 7.5 µL and flow rate of 0.3 mL/min were applied successfully”61.
A run time of 2 min was used keeping the column temperature at 25 °C. Multiple reaction monitoring (MRM)
of the transition pairs of m/z 399.1 to 153.0 for OG, m/z 358.2 to 134.1 for TG and m/z 340.2 to 116.1 for IS in
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Figure 3. Blank plasma (a) and blank brain homogenate (b) samples using LC-MS/MS.
the positive mode utilizing Electro Spray Ionization (ESI) was implemented62. “The following parameters were
applied: turbo ions spray at 400 °C, capillary temperature at 275 °C, sheath and auxiliary gas at 15 and 2 psi, respectively, ion spray voltage of 3800 V, capillary voltage of 4 KV, capillary offset of 35 and de-solvating line temperature
at 400 °C”62.

Calibrators and QC samples.

Stock solutions of OG & TG (1 mg/mL) were prepared separately in methanol and serially diluted with methanol to prepare working solutions of OG & TG (0.5, 1.2, 1.5, 7.0, 14.0, 15.0,
18.0, 25.0 & 28.0 µg/mL) and stored at 4 °C. Ten microliters of the prepared working solution was spiked with
90 µL blank plasma or blank brain homogenate (10%) to make the corresponding standard or QC samples. The
final concentrations for calibrators were 50 (LLOQ), 150, 700, 1400, 1800 and 2800 ng/mL, and for QC samples
were 120 (LQC), 1500 (MQC) and 2500 ng/mL (HQC). Protein precipitation with acetonitrile was used for the
processing of the calibrators & QC samples with full details under the sample preparation section. Calibration
curves were obtained by plotting Peak Area Ratios (PAR) of each drug to IS, against the corresponding concentrations (C) of the drug.

Sample preparation.

A reported direct extraction method was used63,64 for both OG and TG in the presence of the IS after simple modification so it can be applied for both rats’ plasma and brain homogenate samples.
An aliquot of 100 μL of plasma sample (or brain homogenate 10%) was spiked with 10 μL IS (10 μg/mL), precipitated with 400 μL acetonitrile, vortexed for 2 min, centrifuged at 12.000 rpm for 10 min, then 300 μL of the clear
supernatant layer was diluted with 300 μL water, and stored at −80 °C waiting for analysis63,64.

Bioanalytical validation. Validation was accomplished using US-FDA guidelines by investigating different

QC levels (n = 3). Six calibrators were constructed to satisfy linearity. The final brain samples’ concentrations
were calculated as ng/g brain tissue after considering the dilution factor of 10. Accuracy and precision were
evaluated by analysis different QC samples three times a day (n = 3) & three times on different days (n = 3). The
relative error (RE) and percent relative standard deviations (% RSD) were calculated. Selectivity of the method
was checked by comparing the blank samples with the zero samples and in vivo samples’ chromatograms to
ensure that there is no suppressing interference. Carry over effect was evaluated by injecting high concentration
samples after the blank. Matrix effect was estimated based on the ratio of AUP of post-extracted QC samples &
their corresponding pure solutions while the extraction recovery was estimated by the comparison of the AUP of
extracted QC samples against their post-extracted samples. Moreover, stability of QC samples in the auto-sampler
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Figure 4. Multiple reaction monitoring (MRM) chromatogram of omarigliptin (m/z = 399.1 to 153.0),
trelagliptin (m/z = 358.2 to 134.1) and alogliptin (internal standard, m/z = 340.2 to 116.1): (a) zero plasma
spiked with internal standard; (b) plasma sample spiked with the three drugs at their lower limit of quantitation
(LLOQ).

and short-term stability (room temp., 3 h), Freez-thaw cycles (n = 3) and long-term stability (−80 °C, 2 weeks)
were tested.

In vivo BBB crossing test and determination of brain GLP-1 concentration.

Twenty-four rats (200
grams ± 25) were used in this study. They were randomly allocated into four groups (n = 6); the first received OG
(5 mg/kg, p.o), the second received TG (20 mg/kg, p.o), the third received OG (5 mg/kg, intra-nasal) while the
fourth group was kept as control. Intranasal administration was delivered as previously described by Yang et al.65.
Briefly, rats were anesthetized with pentobarbital sodium (30 mg/kg, i.p.) and kept in a supine position with neck
extended. A volume of 50 μl containing OG was applied to each naris using a 10 μl fine pipette tip. The dose was
calculated for rats according to FDA guidelines for human-rodent dose conversions66 & the safety profile for OG
in humans67. The proposed study considered the LC-MS/MS quantitative determination of OG & TG in plasma
and brain tissue after oral administration to rats (n = 6 for each drug) and evaluated the significant difference for
the intra-nasal route of administration for OG (n = 6) against the oral route by calculating the brain/plasma ratio
for each route. Moreover, a control group (n = 6) was considered while comparing the GLP-1 brain concentration
after the intranasal administration.
The main aim of the study was to check the crossing ability of the mentioned drugs for the BBB and to confirm
that the developed LC-MS/MS method is applicable for the bioassay of the drugs in the actual biological samples
(plasma & brain tissue) after 2 hours. The design of the study is one treatment, one period, single dose study. All
procedures employed in this study were reviewed and approved by the ethics committee of the British University
in Egypt. It is worthy to mention that tween 80 surfactant (2.5%, w/v) was required for OG suspension in saline
(p.o) due to its hydrophobic properties while TG was very soluble. Sodium lauryl sulphate (2.5%, w/v) was used
for the intra-nasal solution to dissolve OG enhancing its penetration and as antimicrobial agent.
After 2 hours of drugs administration, 0.3 mL blood samples were collected into heparinized tubes via rats’ tail
vein (except the control group). The separated plasma (>100 µL) was pipetted to clean tubes and stored at −80 °C
until analysis. All twenty four rats were then sacrificed and the whole brain of each animal was separated, washed
in saline, homogenized (10%, w/v in saline) and kept frozen at −80 °C until LC-MS/MS analysis (groups I-III) &
GLP-1 ELISA kit analysis (groups III & IV). The brain homogenate of groups III & IV was centrifuged at 3000 rpm
SCIENTIFIC RepOrts | (2018) 8:8959 | DOI:10.1038/s41598-018-27395-0
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Figure 5. (a) MRM chromatogram of in vivo rat plasma sample obtained 2 hours after oral administration of
omarigliptin (5 mg/Kg). (b) MRM chromatogram of in vivo rat brain homogenate sample obtained 2 hours after
oral administration of omarigliptin (5 mg/Kg).

for 3 minutes68 then the supernatant was used for determination of GLP-1 concentration using Sandwich ELISA
kit (CUSABIO, CSB-E08117r) according to a reported method69. The dilution factor of ten was considered for all
brain tissue calculations (LC-MS/MS & ELISA).

Statistical analysis. Statistical analysis was performed using a software program (GraphPad Prism, version
5.01, Inc., 2007, San Diego, CA, USA). GLP-1 results were expressed as the mean ± SEM and analyzed using
two-tailed Student’s t-test test. Probability values of less than 0.05 were considered statistically significant.
Ethics statement. All experiments and methods were performed in accordance with relevant guidelines
and regulations. All experimental protocols were reviewed, approved, signed & stamped by a named institutional
ethical committee (The British University in Egypt). Furthermore, after partial validation of the described above
method, it was extended to human subjects’ application. The ethics committee of the British University in Egypt
approved the experimental protocols and informed consents. Moreover, the protocol was registered in clinicaltrials.gov (ID: NCT03362398).

Results

All the calibrators & validation results are shown in (Table 1) in accordance with FDA bioanalytical guidelines44.
Concentration of OG & TG in rats’ plasma (after 2 h, p.o) were found to be 2688.79 & 1754.79 ng/mL, respectively, calculated from the bio-analysis regression equations mentioned in (Table 1), which is in agreement with
previously developed OG & TG pharmacokinetic studies in rats63,64. Only OG crossed the BBB after the oral
administration showing concentration of 621.75 ng/g in brain tissue after considering the dilution factor. The
brain/plasma concentration ratio of 0.23 (621.75/2688.79) was used to deduce the penetration power through
the BBB. Results showed that only OG crossed the BBB efficiently suggesting its possible repositioning as antiparkinsonian agent that will be of interest for researchers interested in Parkinson’s disease. Intra-nasal administration of OG showed significant higher brain/plasma concentration ratio of 0.76 (609.83 ± 103.16 ng/g brain
SCIENTIFIC RepOrts | (2018) 8:8959 | DOI:10.1038/s41598-018-27395-0
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Figure 6. MRM chromatograms of in vivo rats’ brain homogenate 10% samples (n = 6) obtained 2 hours after
intra-nasal administration of omarigliptin (5 mg/Kg) showing concentration of 609.83 ng/g tissue ± 103.16
expressed as mean ± S.E.M (after considering the dilution factor of 10).

tissue/802.35 ± 76.85 ng/mL plasma expressed as mean ± S.E.M) enhancing the ratio by 3.3 folds compared
to the oral route. Mean GLP-1 brain tissue concentration (±S.E.M), for the intranasal group, was found to be
69.32 ± 7.18 pg/g tissue against 26.87 ± 1.59 pg/g for the control group with a significant increase of 2.6 folds compared to the control group (p < 0.001). The dilution factor of ten was considered for all brain tissue calculations
(LC-MS/MS & ELISA).

Discussion

The doses for the underlying repositioning investigation were selected based on previously reported pharmacokinetic studies63,64 and calculated according to FDA human-rats dose conversions’ calculations66. A dose of
5 mg/kg OG for rats will be multiplied by 60 (average human kg) and then divided over 6.2 based on FDA body
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Figure 7. MRM chromatograms of in vivo rats’ plasma samples (n = 6) obtained 2 hours after intra-nasal
administration of omarigliptin (5 mg/Kg) showing concentration of 802.35 ng/mL ± 76.85 expressed as
mean ± S.E.M.

surface area conversions66 resulting in a human dose nearly equals to 50 mg with a reported well tolerated and
safety profile67.
In the present bio-analysis work, OG determination was not studied in the presence of other drugs or metabolites, as it is not a victim of drug-drug interactions or metabolism70. Although many direct precipitation63,64,70
and liquid-liquid35,40,42,71,72 extraction procedures were described in literature for OG and TG bioanalytical assays,
simple direct precipitation with acetonitrile63,64 was selected by the authors and applied successfully for rats’
plasma and extended to the brain homogenate experiments. Figure 2 shows the suggested fragmentation pattern
& daughters for the drugs displaying m/z 153.0 for OG, m/z 134.1 for TG and 116.1 for IS in the positive mode
ESI. The same instrument, column, mobile phase & all the mass detection parameters were adopted from previously reported methods by the same authors61,62. Modification of the extraction procedure by applying 400 µL
acetonitrile and further dilution with 300 µL water enabled similar retention times for both the plasma and brain
SCIENTIFIC RepOrts | (2018) 8:8959 | DOI:10.1038/s41598-018-27395-0
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Item

UPLC-MS/MS

HPLC-UV

Regression Eq.

Y = 14.561 × +310.35

Y = 1070.3 × +30.4

Correlation Co.

0.9999

0.9997

*LOD

6.67 ng/mL

0.67 µg/mL

*LOQ

20 ng/mL

2 µg/mL

Range

20–2700 ng/mL

2–10 µg/mL
—

Accuracy (*R%)

99.88% ± 0.7

Precision (*% RSD)

0.71%

—

Tablets (Marizev )

Recovery = 98.08%

—

®

Table 2. Results obtained for the described UPLC-MS/MS & HPLC-UV methods for determination of OG
in bulk and tablets. *Where LOD is the limit of detection, LOQ is the limit of quantification, R% is the mean
recovery percent and % RSD is the percent relative standard deviation.

®

Figure 8. (a) UPLC-ESI-MS/MS chromatogram of Marizev tablet extract containing 2 µg/mL of omarigliptin
at 1.1 min. (b) HPLC-UV chromatogram of 10 µg/mL omarigliptin in bulk at 2.1 min.

homogenate extracts that was useful to evaluate accurately which drug crossed the BBB. Literature showed that
sitagliptin and linagliptin did not cross the BBB73,74 so working on BBB crossing ability is an interesting point for
gliptins especially after the reported anti-parkinsonian activity of the previously developed gliptins4–9.
All the validation parameters were satisfying according to US-FDA guidelines44. Linearity range of (50–
2800 ng/mL) was enough for successful bioassay of the mentioned drugs in rats’ plasma & brain tissue. Accuracy
& precision of the method was confirmed by RE and % RSD values (Table 1). Selectivity of the method was confirmed by absence of interference after comparison between blank samples (Fig. 3), zero samples (Fig. 4), LLOQ
SCIENTIFIC RepOrts | (2018) 8:8959 | DOI:10.1038/s41598-018-27395-0
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Figure 9. Effect of a single intranasal administration of OG (5 mg/kg) on brain GLP-1 level in rats. Data are
presented as means ± S.E.M. (n = 6). ***p < 0.001 compared to control group (Student’s t-test).

samples (Fig. 4) & in vivo samples (Figs 5, 6 and 7). No carry over was observed when injecting high concentration sample after the blank. The other validation results in (Table 1) confirmed that no significant matrix effect
was observed, acceptable recoveries were obtained & good results were found regarding all the stability studies
(R% below 15% for all variables).
OG & TG concentrations in rats’ plasma were found to be 2688.79 & 1754.79 ng/mL after 2 h from the oral
administration but only OG crossed the BBB showing concentration of 621.75 ng/g in brain tissue after considering the dilution factor of ten due to its low molecular weight & lipophilic properties suggesting its repositioning as
antiparkinsonian agent. The results of BBB crossing will be of interest for researchers interested in Parkinson’s disease. Intranasal brain/plasma ratio of 0.76 showed a promising targeting effect than the oral ratio of 0.23 that may
be attributed to direct crossing of the drug for the olfactory region targeting the cerebrospinal fluid in addition
to BBB crossing after trans-mucosal system absorption. The simple intranasal formulation was developed using
sodium lauryl sulphate surfactant (2.5%, w/v) to solubilize the lipophilic omarigliptin with penetration enhancing
& antimicrobial properties. Intranasal administration (n = 6) showed enhanced brain/plasma ratio by 3.3 folds
than the oral group accompanied with 2.6 folds increase in brain glucagon-like peptide-1 (GLP-1) concentration
than the control group. Parkinson’s disease (PD) is the second most common neurodegenerative disease. This
investigation supported the repositioning of a once-weekly anti-diabetic safe drug for PD treatment enhancing
the patient compliance as well as its economic impact as one dose per week instead of the marketed daily drugs.
The ultimate objective of OG repositioning, in the underlying project, is to overcome the escalating costs, stagnant productivity and protracted timelines to bring therapeutic drugs to the PD market. Not only omarigliptin
enhances the intestinal Glucagon like peptide-1 (GLP-1) but also it crosses BBB enhancing them in the brain
with expected high neuroprotective effects. It is not mandatory for the gliptin to cross the BBB to enhance a neuroprotective effect as it increases GLP-1 & consequently, GLP-1 can cross the BBB. However, crossing the BBB
is a promising breakthrough for gliptins9 that will ensure a double effect, the first from intestinal GLP-1 and the
second from the brain GLP-1 especially through the intranasal route of administration that showed 3.3 folds the
brain/plasma ratio. OG is the first gliptin that crossed BBB either from the oral route or from the intranasal route
and it increased the brain concentration of GLP-1 significantly, which is the main finding of the present work.
Moreover, the developed method in rats’ plasma was extended to human plasma but change in species necessitated a partial validation study based on QC samples with limitation that it covered only the Cmax value and
lower recoveries by around 13% were obtained because of the more complex matrix. Samples from twelve healthy
volunteers were collected at 1.5 h after single oral dose of one Marizev tablet nominally containing 25 mg of
OG or one Zafatek tablet nominally containing 100 mg of TG. The ethics committee of the British University
in Egypt approved the experimental protocols and informed consents. Moreover, the protocol was registered in
clinicaltrials.gov (ID: NCT03362398). The blood glucose levels were monitored for all the human subjects and no
fluctuation was found confirming the anti-hyperglycemic effect of the drugs only in case of high glucose levels as
an advantage instead of the direct hypoglycemic effect of some marketed anti-diabetics. Concentration of OG &
TG in human plasma (after 1.5 h) were found to be 276.4 & 193.44 ng/mL, respectively which is in agreement with
previously developed OG & TG pharmacokinetic studies35,40,42,70–72.
Literature review showed many cases reporting the anti-cancer effect of gliptins confirming its polypharmacology in addition to their anti-diabetic, anti-oxidative, anti-inflammatory & neuro-protective effects.
It is reported that DPP-4 inhibition enhanced the antitumor response to melanoma and diminished tumor
growth75,76. Sitagliptin showed reduction in breast cancer risk in women with type-2 diabetes77. It is documented
that GLP-1 arrests cell proliferation of colon cancer cells suggesting its protective role in colon cancer78. Sitagliptin
also reduced colon carcinogenesis in rats79. Vildagliptin inhibited lung tumor genesis in one study80. Screening
results of sitagliptin and vildagliptin on colon cancer cell lines (HT-29) showed IC 50 values of 31.2 and 125 µg/
mL, respectively81. And as in vitro screening for preliminary drug repositioning is preferable than in vivo methods82,83, In the present investigation, OG & TG were tested against MCF-7 breast cancer cell lines and showed IC
50 values of 125 & 250 µg/mL, respectively (Vacsera, Giza, Egypt). However, the relatively high value of IC 50 and
the absence of potent anticancer activity at lower concentrations, after NCI screening (MD, USA), excluded their
repositioning as potent anticancer agents.
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The authors previously developed LC-MS/MS & LC-UV methods for TG assay in tablets61 while there are no
reported methods for OG assay in tablets. A simple LC-MS/MS method was developed and compared to LC-UV
method at 267 nm for OG assay in pharmaceutical dosage form. All the described chromatographic conditions
and mass detector parameters above were adopted for OG assay in bulk and the results are displayed in (Table 2).
For the LC-UV method, C18 Column (4.6 × 250 mm, 5 µm) was used. The LC-MS/MS method showed higher
sensitivity than LC-UV method so accuracy, precision & pharmaceutical dosage form analysis were applied successfully (Table 2). Figure 8 shows OG retention times of 1.1 & 2.1 min for the LC-MS/MS & LC-UV, respectively.
Finally, Statistical analysis was performed for the effect of a single intranasal administration of OG (5 mg/kg)
on brain GLP-1 level in rats. Data are presented as means ± S.E.M in Fig. 9, (n = 6). ***p < 0.001 compared to
control group. Statistical analysis was performed using a software program (GraphPad Prism, version 5.01, Inc.,
2007, San Diego, CA, USA). GLP-1 results were analyzed using two-tailed Student’s t-test test. Probability values
of less than 0.05 were considered statistically significant.

Conclusion

OG crossed the BBB successfully either after oral administration or intra-nasal route, which suggest its repositioning as antiparkinsonian agent due to many reasons. The first reason is that the first developed gliptins showed
a reported antiparkinsonian activity. Furthermore, its mechanism of action involves rising of GLP-1 and other
hormone levels by inhibiting the degrading enzyme DPP-4 & the increased GLP-1 had a reported and well established potential antiparkinsonian effect. GLP-1 is a potential candidate in modifying neurodegenerative diseases
as a promising antiparkinsonian effect of DPP-4 inhibitors. Finally, as a once-weekly medication, patient compliance will be enhanced with many advantages over the daily marketed drugs especially with intranasal administration that showed enhanced brain/plasma ratio by 3.3 folds than the oral group accompanied with 2.6 folds
increase in brain glucagon-like peptide-1 (GLP-1) concentration than the control group.
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